Rada Savic, PhD

Vice Dean & Professor
Bioengineering
+1 415 502-0640

My research uses computational methods to study the dynamic interplay between disease progression, treatment regimen, and drug and biomarker response across relevant scales (molecule, cell, tissue, organ & whole body) to determine causal links underlying variability in (safety and efficacy) clinical outcomes. By integrating multi-scale, and multi-level clinical data, we aim to determine the right dose, schedule, and treatment duration of various therapies, potentially bringing novel, precise and personalized treatment options to patients with unmet need more quickly.

Publications: 

Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without HIV exposure.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Béranger A, Bekker A, Solans BP, Cotton MF, Mirochnick M, Violari A, Wang J, Cababasay M, Wiesner L, Browning R, Moye J, Capparelli EV, Savic RM, P1106 International Maternal Pediatric and Adolescents AIDS Clinical Trials (IMPAACT) Network

Piperaquine induced QTc prolongation decreases with repeated monthly dihydroartemisinin-piperaquine dosing in pregnant Ugandan women.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Hughes E, Wallender E, Kajubi R, Jagannathan P, Ochieng T, Kakuru A, Kamya MR, Clark TD, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM

Pharmacometrics in tuberculosis: progress and opportunities.

International journal of antimicrobial agents

Wilkins JJ, Svensson EM, Ernest JP, Savic RM, Simonsson USH, McIlleron H

Clinical standards for the dosing and management of TB drugs.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Alffenaar JWC, Stocker SL, Forsman LD, Garcia-Prats A, Heysell SK, Aarnoutse RE, Akkerman OW, Aleksa A, van Altena R, de Oñata WA, Bhavani PK, Van't Boveneind-Vrubleuskaya N, Carvalho ACC, Centis R, Chakaya JM, Cirillo DM, Cho JG, D Ambrosio L, Dalcolmo MP, Denti P, Dheda K, Fox GJ, Hesseling AC, Kim HY, Köser CU, Marais BJ, Margineanu I, Märtson AG, Torrico MM, Nataprawira HM, Ong CWM, Otto-Knapp R, Peloquin CA, Silva DR, Ruslami R, Santoso P, Savic RM, Singla R, Svensson EM, Skrahina A, van Soolingen D, Srivastava S, Tadolini M, Tiberi S, Thomas TA, Udwadia ZF, Vu DH, Zhang W, Mpagama SG, Schön T, Migliori GB

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Imperial MZ, Nedelman JR, Conradie F, Savic RM

Drug concentration at the site of disease in children with pulmonary tuberculosis.

The Journal of antimicrobial chemotherapy

Lopez-Varela E, Abulfathi AA, Strydom N, Goussard P, van Wyk AC, Demers AM, Deventer AV, Garcia-Prats AJ, van der Merwe J, Zimmerman M, Carter CL, Janson J, Morrison J, Reuter H, Decloedt EH, Seddon JA, Svensson EM, Warren R, Savic RM, Dartois V, Hesseling AC

Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townley E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, Langat D, Chalermchockcharoentkit A, Kamthunzi P, Gupta A, Dooley KE, IMPAACT 2001 Study Team

Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Radtke KK, Hesseling AC, Winckler JL, Draper HR, Solans BP, Thee S, Wiesner L, van der Laan LE, Fourie B, Nielsen J, Schaaf HS, Savic RM, Garcia-Prats AJ

Characterizing HIV-preventive, plasma tenofovir concentrations. A pooled participant-level data analysis from HIV pre-exposure prophylaxis (PrEP) clinical trials.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Garcia-Cremades M, Vucicevic K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM

Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.

CPT: pharmacometrics & systems pharmacology

Savic RM, Green ML, Jorga K, Zager M, Washington CB

Pharmacokinetics and Safety of Bedaquiline in HIV-Positive and Negative Older Children and Adolescents with Rifampicin-Resistant Tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Hughes JA, Solans BP, Draper HR, Schaaf HS, Winckler JL, van der Laan L, Radtke KK, Fourie B, Wiesner L, Hesseling AC, Savic RM, Garcia-Prats AJ

Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis.

Expert review of clinical pharmacology

Radtke KK, Svensson EM, van der Laan LE, Hesseling AC, Savic RM, Garcia-Prats AJ

A rabbit model to study antibiotic penetration at the site of infection for non-tuberculous mycobacterial lung disease: macrolide case study.

Antimicrobial agents and chemotherapy

Kaya F, Ernest JP, LoMauro K, Gengenbacher M, Madani A, Aragaw WW, Zimmerman MD, Sarathy JP, Alvarez N, Daudelin I, Wang H, Lanni F, Weiner DM, Via LE, Barry CE, Olivier KN, Dick T, Podell BK, Savic RM, Dartois V

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis.

Open forum infectious diseases

Yun HY, Chang V, Radtke KK, Wang Q, Strydom N, Chang MJ, Savic RM

Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.

American journal of respiratory and critical care medicine

Imperial MZ, Phillips PPJ, Nahid P, Savic RM

Emerging Therapeutics, Technologies, and Drug Development Strategies to Address Patient Nonadherence and Improve Tuberculosis Treatment.

Annual review of pharmacology and toxicology

Garcia-Cremades M, Solans BP, Strydom N, Vrijens B, Pillai GC, Shaffer C, Thomas B, Savic RM

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.

Trials

Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ

Is Glycemic Control the Secret to Tuberculosis Control?

American journal of respiratory and critical care medicine

Huddart S, Savic RM, Cattamanchi A

Optimising pyrazinamide for the treatment of tuberculosis.

The European respiratory journal

Zhang N, Savic RM, Boeree MJ, Peloquin C, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PP, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE

Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis.

Antimicrobial agents and chemotherapy

Ernest JP, Sarathy J, Wang N, Kaya F, Zimmerman MD, Strydom N, Wang H, Xie M, Gengenbacher M, Via LE, Barry CE, Carter CL, Savic RM, Dartois V

A Longitudinal Model-Based Biomarker Analysis of Exposure Response in Adults with Pulmonary Tuberculosis.

Antimicrobial agents and chemotherapy

Gewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, Nsubuga P, Dorman S, Weiner M, Savic RM, Tuberculosis Trials Consortium of the Centers for Disease Control Prevention

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.

The Journal of infectious diseases

Bigelow KM, Deitchman AN, Li SY, Barnes-Boyle K, Tyagi S, Soni H, Dooley KE, Savic R, Nuermberger EL

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.

Nature communications

Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, Rossmassler K, Ramey ME, Bauman AA, Ozols V, Bearrows SC, Schoolnik G, Dolganov G, Garcia B, Musisi E, Worodria W, Huang L, Davis JL, Nguyen NV, Nguyen HV, Nguyen ATV, Phan H, Wilusz C, Podell BK, Sanoussi ND, de Jong BC, Merle CS, Affolabi D, McIlleron H, Garcia-Cremades M, Maidji E, Eshun-Wilson F, Aguilar-Rodriguez B, Karthikeyan D, Mdluli K, Bansbach C, Lenaerts AJ, Savic RM, Nahid P, Vásquez JJ, Voskuil MI

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

The New England journal of medicine

Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group , Tuberculosis Trials Consortium

Malaria PK/PD and the role pharmacometrics can play in the global health arena: Malaria treatment regimens for vulnerable populations.

Clinical pharmacology and therapeutics

Hughes E, Wallender E, Ali AM, Jagannathan P, Savic RM

COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Garcia-Prats AJ, Salazar-Austin N, Conway JH, Radtke K, LaCourse SM, Maleche-Obimbo E, Hesseling AC, Savic RM, Nachman S

Visualizing the dynamics of tuberculosis pathology using molecular imaging.

The Journal of clinical investigation

Ordonez AA, Tucker EW, Anderson CJ, Carter CL, Ganatra S, Kaushal D, Kramnik I, Lin PL, Madigan CA, Mendez S, Rao J, Savic RM, Tobin DM, Walzl G, Wilkinson RJ, Lacourciere KA, Via LE, Jain SK

Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.

The Journal of antimicrobial chemotherapy

Weiner M, Gelfond J, Johnson-Pais TL, Engle M, Johnson JL, Whitworth WC, Bliven-Sizemore E, Nsubuga P, Dorman SE, Savic R, Pharmacokinetics/Pharmacodynamics Group of Tuberculosis Trials Consortium

A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention.

CPT: pharmacometrics & systems pharmacology

Jayachandran P, Garcia-Cremades M, Vucicevic K, Bumpus NN, Anton P, Hendrix C, Savic R

Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data.

Pharmaceuticals (Basel, Switzerland)

Kang WH, Lee JY, Chae JW, Lee KR, Baek IH, Kim MS, Back HM, Jung S, Shaffer C, Savic R, Yun HY

Piperaquine exposure is altered by pregnancy, HIV and nutritional status in Ugandan women.

Antimicrobial agents and chemotherapy

Hughes E, Imperial M, Wallender E, Kajubi R, Huang L, Jagannathan P, Zhang N, Kakuru A, Natureeba P, Mwima MW, Muhindo M, Mwebaza N, Clark TD, Opira B, Nakalembe M, Havlir D, Kamya M, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM

Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.

American journal of respiratory and critical care medicine

Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM

Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.

Clinical pharmacology and therapeutics

Nicol MR, Joshi A, Rizk ML, Sabato PE, Savic RM, Wesche D, Zheng JH, Cook J

Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis.

PLoS computational biology

Fors J, Strydom N, Fox WS, Keizer RJ, Savic RM

Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.

Annual review of pharmacology and toxicology

Ernest JP, Strydom N, Wang Q, Zhang N, Nuermberger E, Dartois V, Savic RM

Response to "Quantitative clinical pharmacology input to SARS-CoV-2 therapeutics should be based on robust data".

Clinical pharmacology and therapeutics

Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Savic RM

Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.

Clinical pharmacology and therapeutics

Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, Luetkemeyer A, Savic RM

Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis.

Antimicrobial agents and chemotherapy

Walsh KF, McAulay K, Lee MH, Vilbrun SC, Mathurin L, Francois DJ, Zimmerman M, Kaya F, Zhang N, Saito K, Ocheretina O, Savic R, Dartois V, Johnson WD, Pape JW, Nathan C, Fitzgerald DW

Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.

Journal of acquired immune deficiency syndromes (1999)

Lee SA, Telwatte S, Hatano H, Kashuba ADM, Cottrell ML, Hoh R, Liegler TJ, Stephenson S, Somsouk M, Hunt PW, Deeks SG, Yukl S, Savic RM

Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.

The lancet. HIV

Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, Wolf L, Sebe M, Likoti M, Fyvie MJ, Shibambo I, Beattie T, Chaisson RE, Churchyard GJ

Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.

Antimicrobial agents and chemotherapy

Zhang N, Strydom N, Tyagi S, Soni H, Tasneen R, Nuermberger EL, Savic RM

Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer.

Translational oncology

Knox SJ, Jayachandran P, Keeling CA, Stevens KJ, Sandhu N, Stamps-DeAnda SL, Savic R, Shura L, Buyyounouski MK, Grimes K

Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.

The Lancet. Child & adolescent health

Radtke KK, Dooley KE, Dodd PJ, Garcia-Prats AJ, McKenna L, Hesseling AC, Savic RM

Accuracy of point-of-care ultrasound by pediatric emergency physicians for testicular torsion.

Journal of pediatric urology

Friedman N, Pancer Z, Savic R, Tseng F, Lee MS, Mclean L, Bagli DJ, Tessaro MO

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.

PLoS medicine

Garcia-Prats AJ, Schaaf HS, Draper HR, Garcia-Cremades M, Winckler J, Wiesner L, Hesseling AC, Savic RM

Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.

Antimicrobial agents and chemotherapy

Sarathy J, Blanc L, Alvarez-Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang HP, Prideaux B, Dietzold J, Salgame P, Savic RM, Linderman J, Kirschner D, Pienaar E, Dartois V

Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.

PLoS medicine

Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE, Zimmerman M, Dartois V, Savic RM

Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.

Antimicrobial agents and chemotherapy

Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Nature medicine

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM

High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types.

eLife

Blanc L, Daudelin IB, Podell BK, Chen PY, Zimmerman M, Martinot AJ, Savic RM, Prideaux B, Dartois V

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Nature medicine

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM

Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial.

Clinical pharmacology and therapeutics

Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM

Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT

Impact of immunopathology on the antituberculous activity of pyrazinamide.

The Journal of experimental medicine

Blanc L, Sarathy JP, Alvarez Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Sacchettini J, Savic RM, Gengenbacher M, Podell BK, Prideaux B, Ioerger T, Dick T, Dartois V

Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.

Science translational medicine

Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE

Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.

The Journal of infectious diseases

Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.

Clinical pharmacology and therapeutics

Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Antimicrobial agents and chemotherapy

Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.

Clinical pharmacokinetics

Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Breast cancer research : BCR

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L

Tuberculous meningitis.

Nature reviews. Neurology

Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Clinical and translational science

Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM

Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.

Antimicrobial agents and chemotherapy

Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Clinical pharmacology and therapeutics

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

CPT: pharmacometrics & systems pharmacology

Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Pérez Ruixo JJ, Plan EL, Savic R, van Hasselt JG, Weber B, Zhou C, Comets E, Mentré F

Importance of Drug Pharmacokinetics at the Site of Action.

Clinical and translational science

Rizk ML, Zou L, Savic RM, Dooley KE

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.

The Lancet. Haematology

Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.

Journal of clinical microbiology

Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P

A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.

Clinical pharmacology and therapeutics

Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, Kubo M, Maeda S, Davis RL, Roden DM, Hedderson MM, Giacomini KM, Savic RM

The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Clinical pharmacokinetics

Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM, Giacomini KM

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

PloS one

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE

GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, Thwaites GE, Boulware DR

Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model.

Pharmaceutical research

Larsen MS, Keizer R, Munro G, Mørk A, Holm R, Savic R, Kreilgaard M

Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

The lancet. HIV

Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic R, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Clinical pharmacology and therapeutics

Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE

Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.

Malaria journal

Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F

Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

ACS infectious diseases

Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE, Dartois V

Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Antimicrobial agents and chemotherapy

Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW

The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

The Pediatric infectious disease journal

Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

American journal of respiratory and critical care medicine

Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M

Designing drug trials: considerations for pregnant women.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M

Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.

Journal of acquired immune deficiency syndromes (1999)

Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Antimicrobial agents and chemotherapy

Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW

Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.

Clinical pharmacology and therapeutics

Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, Brett C, Maeda S, Simpson MD, Hedderson MM, Davis RL, Roden DM, Giacomini KM, Savic RM

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.

Antimicrobial agents and chemotherapy

Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE

Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection.

Journal of the Pediatric Infectious Diseases Society

Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Journal of clinical pharmacology

Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F

Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J

Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Journal of pharmaceutical sciences

Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Clinical pharmacology and therapeutics

Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F

The pharmacokinetics of oxypurinol in people with gout.

British journal of clinical pharmacology

Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO

Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology.

Journal of pharmacokinetics and pharmacodynamics

Delattre M, Savic RM, Miller R, Karlsson MO, Lavielle M

Standard Error of Empirical Bayes Estimate in NONMEM® VI.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Kang D, Bae KS, Houk BE, Savic RM, Karlsson MO

Performance in population models for count data, part II: a new SAEM algorithm.

Journal of pharmacokinetics and pharmacodynamics

Savic R, Lavielle M

Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Journal of pharmacokinetics and pharmacodynamics

Baverel PG, Savic RM, Wilkins JJ, Karlsson MO

Semiparametric distributions with estimated shape parameters.

Pharmaceutical research

Petersson KJ, Hanze E, Savic RM, Karlsson MO

Evaluation of the nonparametric estimation method in NONMEM VI.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Savic RM, Kjellsson MC, Karlsson MO

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Antimicrobial agents and chemotherapy

Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Journal of pharmacokinetics and pharmacodynamics

Savic RM, Jonker DM, Kerbusch T, Karlsson MO

Diagnosing model diagnostics.

Clinical pharmacology and therapeutics

Karlsson MO, Savic RM

Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.

Journal of clinical pharmacology

Osterberg O, Savic RM, Karlsson MO, Simonsson US, Nørgaard JP, Walle JV, Agersø H

Application of population pharmacokinetics to cladribine.

BMC pharmacology

Lindemalm S, Savic RM, Karlsson MO, Juliusson G, Liliemark J, Albertioni F